Antipodes Partners LTD Humacyte, Inc. Transaction History
Antipodes Partners LTD
- $4.06 Billion
- Q3 2025
A detailed history of Antipodes Partners LTD transactions in Humacyte, Inc. stock. As of the latest transaction made, Antipodes Partners LTD holds 8,125 shares of HUMA stock, worth $9,587. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,125
Previous 7,174
13.26%
Holding current value
$9,587
Previous $14,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding HUMA
# of Institutions
157Shares Held
43.2MCall Options Held
383KPut Options Held
648K-
Vanguard Group Inc Valley Forge, PA7.52MShares$8.87 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.14MShares$8.43 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.1MShares$3.65 Million0.0% of portfolio
-
State Street Corp Boston, MA2.41MShares$2.84 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.1MShares$2.47 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $122M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...